GlassScriptPhysician profile
Ibrahim H Sbeitan
NPI 1558367110
$9,920.24
in general payments reported to CMS, 2019-2025
55 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,316 · 2020: $430 · 2021: $2,109 · 2022: $1,582 · 2023: $2,001 · 2024: $1,314 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.72 |
| Education | $312.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,717.46 | 2019-2024 | Opdivo, Opdualag, Augtyro |
| Taiho Oncology, INC. | $1,176.73 | 2021-2023 | |
| Astellas Pharma US INC | $641.73 | 2019-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $526.04 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Lilly USA, LLC | $508.59 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $438.23 | 2019-2024 | Opdivo, Reblozyl, Pomalyst |
| Incyte Corporation | $359.16 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $347.61 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $304.01 | 2019-2024 | |
| Beigene USA, INC. | $281.47 | 2021-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $267.87 | 2019-2023 | Iclusig, Alunbrig |
| Janssen Biotech, INC. | $257.57 | 2019-2024 | Rybrevant, Erleada, Akeega |
| Eisai INC. | $248.94 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $232.49 | 2019-2023 | Imbruvica |
| Kite Pharma, INC. | $220.18 | 2019-2024 | Yescarta |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $203.25 | 2020-2024 | Enhertu, Vanflyta, Injectafer |
| Glaxosmithkline, LLC. | $182.64 | 2022-2024 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $182.38 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Adc Therapeutics America, INC. | $153.72 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $124.36 | 2019-2024 | Keytruda |
| Seagen INC. | $115.91 | 2019-2023 | Tukysa, Adcetris |
| Amgen INC. | $111.62 | 2019-2023 | Kyprolis, Blincyto |
| Foundation Medicine, INC. | $109.06 | 2019-2023 | |
| Abbvie INC. | $100.43 | 2019-2024 | Venclexta |
| Exelixis INC. | $86.42 | 2019-2023 | Cabometyx |
| Secura Bio, INC. | $83.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.33 | 2019-2022 | |
| Array Biopharma INC | $58.13 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $53.23 | 2019-2022 | |
| Coherus Oncology, INC. | $53.17 | 2023-2024 | |
| Genzyme Corporation | $45.89 | 2019-2023 | |
| Medtronic USA, INC. | $44.52 | 2019 | |
| Genmab U.S., INC. | $43.08 | 2024-2025 | Epkinly, Tivdak |
| Gilead Sciences, INC. | $41.26 | 2019-2024 | |
| Tesaro, INC. | $38.98 | 2019 | |
| Cti Biopharma Corp. | $35.48 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $34.06 | 2021-2023 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $33.87 | 2022 | |
| Stryker Corporation | $32.03 | 2023 | Optablate |
| Aurobindo Pharma USA, INC. | $31.67 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $29.68 | 2024 | Libtayo |
| Myriad Genetic Laboratories, INC. | $29.54 | 2023 | Precisetumor |
| Pharmaessentia USA Corporation | $29.45 | 2023 | Besremi |
| Clovis Oncology, INC. | $27.38 | 2019 | |
| Acrotech Biopharma INC. | $25.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.43 | 2019 | |
| G1 Therapeutics, INC. | $22.88 | 2022 | |
| Asd Specialty Healthcare, LLC | $20.32 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.15 | 2023 | Monoferric |
| Acceleron Pharma, INC. | $17.14 | 2021 | |
| Myovant Sciences INC. | $16.87 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.74 | 2019 | |
| Puma Biotechnology, INC. | $15.38 | 2019 | |
| Servier Pharmaceuticals LLC | $13.78 | 2024 | |
| Octapharma USA, INC. | $13.23 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Sbeitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.